Invention Grant
- Patent Title: Recombinant Zika vaccines
-
Application No.: US16063239Application Date: 2016-12-23
-
Publication No.: US11110162B2Publication Date: 2021-09-07
- Inventor: Erich Tauber , Sabrina Schrauf , Matthias Müllner , Katrin Ramsauer , Angelika Irmler , Patrick Csar
- Applicant: Themis Bioscience GmbH
- Applicant Address: AT Vienna
- Assignee: Themis Bioscience GmbH
- Current Assignee: Themis Bioscience GmbH
- Current Assignee Address: AT Vienna
- Agency: Seed Intellectual Property Law Group LLP
- Priority: EP15202480 20151223,EP16162688 20160329
- International Application: PCT/EP2016/082659 WO 20161223
- International Announcement: WO2017/109222 WO 20170629
- Main IPC: A61K39/12
- IPC: A61K39/12 ; A61P31/14 ; A61K39/165 ; C12N7/00 ; C12N15/86 ; B01D15/38 ; B01J20/282 ; C12N7/02 ; B01D15/36

Abstract:
The present invention relates to the provision of immunogenic or vaccine compositions comprising at least one recombinant Zika virus antigen, wherein the at least one recombinant Zika virus antigen is encoded by at least one nucleic acid sequence encoding at least one E-protein of a Zika virus or a functional fragment thereof. Further provided are nucleic acid molecules and a recombinant chimeric virus encoding and/or comprising selected antigens from a Zika virus, which are suitable as vaccine compositions. Preferably, the sequences encoding at least one Zika virus antigens suitable for eliciting an immune response are operably linked to a non-flavivirus derived vector backbone. Further provided are methods for purifying the recombinant chimeric virus particles or the immunogenic composition. Finally, there is provided an immunogenic/vaccine composition for use in a method of preventing or treating a Zika virus disease.
Public/Granted literature
- US20190083601A1 RECOMBINANT ZIKA VACCINES Public/Granted day:2019-03-21
Information query